Remove 2016 Remove CMS Remove Exercise
article thumbnail

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

DAIC

Building on an investment made in 2016, Edwards has exercised its option to acquire Endotronix , a leader in heart failure (HF) management solutions. A CMS national coverage determination is expected in early 2025. Many structural heart patients Edwards serves today also suffer from HF with limited options.